Toward victory in adult ALL: blinatumomab joins in
Author:
Affiliation:
1. OSPEDALE DELL'ANGELO AND SS GIOVANNI E PAOLO
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/120/26/5094/1361394/zh805212005094.pdf
Reference10 articles.
1. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL).;Topp;Blood,2012
2. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.;Bargou;Science,2008
3. Prognostic factors in adult acute lymphoblastic leukemia.;Rowe;Br J Haematol,2010
4. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).;Bassan;Blood,2009
5. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.;Gökbuget;Blood,2012
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia;Leukemia & Lymphoma;2024-08-18
2. Approved Protein Therapeutics and Their Biochemical Targets;Protein-based Therapeutics;2023
3. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials;Journal of Clinical Pharmacy and Therapeutics;2022-07-29
4. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease;Seminars in Hematology;2020-07
5. Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia;Frontiers in Immunology;2019-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3